Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Iron chelation therapy

A V Hoffbrand1

  • 1Royal Free Hospital School of Medicine, London, UK.

Current Opinion in Hematology
|March 1, 1995
PubMed
Summary
This summary is machine-generated.

Iron chelating drugs are crucial for managing iron overload in transfusion-dependent anemias. L1 (deferiprone) shows promise as an oral iron chelator, but safety concerns require further investigation.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Okadaic acid-induced apoptosis of HL60 leukemia cells is preceded by destabilization of bcl-2 mRNA and downregulation of bcl-2 protein.

FEBS letters·1998
Same author

New approaches to the management of hepatitis and endocrine disorders in Cooley's anemia.

Annals of the New York Academy of Sciences·1998
Same author

Iron chelation therapy: the need for orally active drugs.

The Journal of laboratory and clinical medicine·1998
Same author

Herbimycin A accelerates the induction of apoptosis following etoposide treatment or gamma-irradiation of bcr/abl-positive leukaemia cells.

Oncogene·1998
Same author

Lack of clonal BCRA2 gene deletion on chromosome 13 in chronic lymphocytic leukaemia: an update of recent scientific reports.

British journal of haematology·1998
Same author

Long-term trial of deferiprone in 51 transfusion-dependent iron overloaded patients.

Blood·1998
Same journal

Dynamic myeloid suppressor states in cancer and inflammation and their therapeutic potential.

Current opinion in hematology·2026
Same journal

Factor XIa inhibition for the prevention of thrombosis: mechanism, clinical trial signals, and indication-specific positioning.

Current opinion in hematology·2026
Same journal

Nutrition as a regulator of hematopoietic stem cell biology and transplantation.

Current opinion in hematology·2026
Same journal

From biomimicry to clinical actionability: rethinking high-shear thrombosis as a mechanobiological system.

Current opinion in hematology·2026
Same journal

Bidirectional relationship between metabolic and thrombotic disease mechanisms.

Current opinion in hematology·2026
Same journal

The dual role of the brain-derived neurotrophic factor as a regulator of hemostasis and thrombotic risk.

Current opinion in hematology·2026
See all related articles

Area of Science:

  • Pharmacology
  • Hematology
  • Toxicology

Background:

  • Iron chelation therapy is vital for preventing cardiac toxicity in patients with thalassemia major and other anemias requiring regular blood transfusions.
  • Iron chelators have potential applications in treating neoplastic diseases, reducing free radical damage, and as adjuncts to other therapies.
  • The current standard, desferrioxamine, is administered parenterally and is expensive, limiting its accessibility worldwide.

Purpose of the Study:

  • To evaluate the efficacy and safety of orally active iron chelating agents.
  • To address the need for an inexpensive, orally available iron chelator as an alternative to desferrioxamine.

Main Methods:

  • Clinical studies and experimental data were reviewed to assess the therapeutic value of iron chelators.

Related Experiment Videos

  • L1 (deferiprone) was investigated for its oral activity and efficiency compared to desferrioxamine.
  • Adverse side-effects of L1, including agranulocytosis and arthropathy, were noted for further evaluation.

    • Main Results:

    • L1 (deferiprone) demonstrated comparable efficiency to desferrioxamine in both short- and long-term clinical studies.
    • Despite its efficacy, L1 has shown adverse side-effects, necessitating further safety trials.
    • No other orally active iron chelator has proven as effective or safe as L1 in clinical trials to date.

    Conclusions:

    • L1 (deferiprone) represents a significant advancement as an orally active iron chelator.
    • Further clinical trials are essential to fully assess the safety profile of L1 and manage potential toxicities.
    • The development of safe and effective oral iron chelators remains a critical area of research for managing iron overload disorders.